# Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout

> **NCT00174967** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 153 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** Placebo
- **DRUG:** Febuxostat
- **DRUG:** Febuxostat
- **DRUG:** Febuxostat

## Key facts

- **NCT ID:** NCT00174967
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** 2001-07
- **Final completion:** 2001-07
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2011-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00174967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00174967, "Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00174967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*